Login
$INBX
$95.66 +$7.05 (7.96%) Close

Company Executives

$INBX Management Team

Mr. Mark Lappe

Chairman of the Board of Director

President

Chief Executive Officer

Co-Founder

Age 56
Compensation $1.023M USD
Sex Male

Dr. Brendan Eckelman

Co-Founder

Chief Scientific Officer

Age 44
Compensation $704.0K USD
Sex Male

Ms. Kelly Deck

Chief Financial Officer

Age 43
Compensation $1.022M USD
Sex Female
Directors
5
serving now
Independent
4 of 5
stated in the proxy
Average tenure
Not stated
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2025 pay Source
Douglas G. Forsyth
Not stated Not stated Independent
Compensation Committee
None stated $202,685
Kimberly Manhard
Not stated Not stated Independent
Compensation Committee Nominating and Corporate Governance Committee
None stated $183,685
Mark P. Lappe
Not stated Not stated Not independent None stated None stated Paid as CEO
Jon Faiz Kayyem, Ph.D.
Not stated Not stated Independent
Audit Committee
None stated $192,185
Kristiina Vuori, M.D., Ph.D.
Not stated Not stated Independent
Audit Committee Nominating and Corporate Governance Committee
None stated $186,185

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed Apr 23, 2026
Former Parent
former parent that retained an equity interest in the Company of 8% upon the Distribution
Amount not stated

Transition Services Agreement under which the Company provided transition services to the Former Parent and other Sanofi entities following the Separation

With the Company Open in proxy
Former Parent
former parent that retained an equity interest in the Company of 8% upon the Distribution
$1.0 million
2024

Former Parent reimbursed the Company for severance payments made to former employees under the Transition Services Agreement

With the Company Open in proxy
Former Parent
former parent that retained an equity interest in the Company of 8% upon the Distribution
Amount not stated

Pharmacovigilance Agreement entered into with the Former Parent for sharing information for regulatory and pharmacovigilance compliance

With the Company Open in proxy
Brendan P. Eckelman, Ph.D.
former Chief Scientific Officer of the Company; founder, chief executive officer and beneficial owner of significant equity interests in Scithera
$1.3 million
2025

License and Assignment Agreement licensing Company antibody library assets to Scithera for an up-front payment, milestone payments and royalties, and a Materials and Know-How Transfer Agreement

With Scithera, Inc. Open in proxy
directors and officers of the Company
directors and officers of the Company
Amount not stated

Indemnification agreements requiring the Company to indemnify each director and executive officer to the fullest extent permitted by law and the Certificate of Incorporation and Bylaws

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support